Polynovo Ltd

Healthcare AU PNV

2.15AUD
0.04(1.90%)

Last update at 2024-05-29T02:56:00Z

Day Range

2.102.17
LowHigh

52 Week Range

1.092.52
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -4.93310M -1.15092M -4.55040M -4.12710M -3.18989M
Minority interest - - - - -
Net income -4.92454M -1.19253M -4.60503M -4.19374M -1.81597M
Selling general administrative 50.84M 28.58M 24.05M 19.57M 11.87M
Selling and marketing expenses 2.36M 1.26M 0.80M 0.80M 0.83M
Gross profit 60.81M 39.24M 27.60M 20.45M 12.06M
Reconciled depreciation 2.04M 1.59M 0.92M 0.84M 0.31M
Ebit -4.74698M 0.54M -4.32777M -4.10910M -4.56381M
Ebitda -2.70952M 2.13M -3.40709M -3.27192M -4.25421M
Depreciation and amortization 2.04M 1.59M 0.92M 0.84M 0.31M
Non operating income net other - - - - -
Operating income -5.08856M 0.54M -4.23010M -4.04543M -4.56381M
Other operating expenses 47.03M 26.83M 23.16M 18.13M 17.91M
Interest expense 0.19M 0.32M 0.22M 0.02M 0.02M
Tax provision -0.00856M 0.04M 0.05M 0.07M 0.00000M
Interest income 0.87M 0.00067M 0.00110M 0.06M 0.35M
Net interest income 0.16M -0.31470M -0.32030M 0.02M 0.33M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00856M 0.04M 0.05M 0.07M -1.37392M
Total revenue 65.24M 41.44M 29.16M 22.16M 13.35M
Total operating expenses 66.99M 39.49M 30.75M 24.59M 16.62M
Cost of revenue 4.43M 2.20M 1.56M 1.70M 1.29M
Total other income expense net 1.10M -0.57957M -1.08261M 0.09M 1.37M
Discontinued operations - - - - -
Net income from continuing ops -4.92454M -1.19253M -4.60503M -4.19374M -3.18989M
Net income applicable to common shares -4.92454M -1.19253M -4.60503M -4.19374M -3.18989M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 92.62M 34.97M 38.34M 37.86M 28.23M
Intangible assets 1.16M 1.40M 1.65M 1.90M 2.15M
Earning assets - - - - -
Other current assets 0.31M 0.15M 0.15M 0.78M 0.49M
Total liab 27.24M 17.26M 15.99M 14.04M 2.13M
Total stockholder equity 65.38M 17.72M 22.35M 23.81M 26.10M
Deferred long term liab 0.18M 0.33M 0.48M - -
Other current liab 9.93M 5.93M 6.84M 7.86M 1.48M
Common stock 191.59M 139.43M 139.25M 139.07M 139.07M
Capital stock 191.59M 139.43M 139.25M 139.07M 139.07M
Retained earnings -121.37831M -116.45377M -115.26124M -110.65621M -106.45911M
Other liab 0.42M 0.29M 0.22M 0.17M 0.07M
Good will - - - - -
Other assets 0.74M 0.63M 0.62M 0.14M 0.17M
Cash 46.85M 6.10M 7.69M 11.65M 13.92M
Cash and equivalents - - - - -
Total current liabilities 12.67M 7.76M 8.65M 9.47M 2.06M
Current deferred revenue -1.89014M -1.83418M -2.87537M -5.62825M -5.62825M
Net debt -30.80326M 4.89M 2.31M -1.61590M -3.88890M
Short term debt 1.89M 1.79M 2.88M 5.63M 5.63M
Short long term debt 1.40M 1.33M 2.53M 5.30M -
Short long term debt total 16.04M 10.99M 10.00M 10.03M 10.03M
Other stockholder equity -70.21300M -22.97673M -23.98926M -28.41429M -6.51191M
Property plant equipment 23.37M 16.75M 19.82M 16.54M 6.01M
Total current assets 67.35M 16.19M 16.24M 19.28M 19.90M
Long term investments 0.56M 0.30M 0.14M 0.14M 0.17M
Net tangible assets 64.23M 16.31M 20.70M 21.91M 23.95M
Short term investments 0.05M 0.05M 0.05M 0.05M 0.05M
Net receivables 13.69M 6.09M 5.67M 3.14M 3.96M
Long term debt 1.79M 2.80M 5.06M 1.98M -
Inventory 4.53M 2.54M 1.96M 1.22M 1.22M
Accounts payable 2.74M 1.87M 1.81M 1.61M 0.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.82986M -5.26164M -1.63722M -4.60227M -6.51191M
Additional paid in capital - - - - -
Common stock total equity - - - 139.07M 139.07M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 0.33M 0.48M -18.43707M 8.33M
Deferred long term asset charges - - - - -
Non current assets total 25.27M 18.78M 22.10M 18.58M 8.33M
Capital lease obligations 12.86M 6.86M 2.41M 2.74M -
Long term debt total 14.15M 9.21M 7.12M 4.40M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.84877M 5.86M -3.56723M -8.84446M 19.00M
Change to liabilities 4.17M -0.14233M 1.79M 1.03M 1.57M
Total cashflows from investing activities -0.84877M 5.86M -3.56723M -8.84446M 13.06M
Net borrowings -3.98661M -5.56831M -0.25037M 7.03M 7.03M
Total cash from financing activities 48.06M -5.38831M -0.07037M 7.03M 0.95M
Change to operating activities 0.10M 0.80M 0.48M 0.57M -0.79989M
Net income -4.92454M -1.19253M -4.60503M -4.19374M -3.18989M
Change in cash 40.74M -1.58636M -3.95915M -2.27299M 10.77M
Begin period cash flow 6.10M 7.69M 11.65M 13.92M 3.15M
End period cash flow 46.85M 6.10M 7.69M 11.65M 13.92M
Total cash from operating activities -6.61253M -2.05703M -0.25022M -0.42732M -3.36973M
Issuance of capital stock 52.05M 0.18M 0.18M - 0.95M
Depreciation 2.28M 1.80M 1.12M 0.84M 0.31M
Other cashflows from investing activities 0.68M 0.00040M 0.00148M 0.02M 0.58M
Dividends paid - - - - -
Change to inventory -1.99499M -0.57546M -0.74279M -0.00159M -0.13186M
Change to account receivables -7.42715M -0.27607M -2.36737M -0.87052M -1.00764M
Sale purchase of stock 52.05M 0.18M 0.18M 0.00000M 0.95M
Other cashflows from financing activities -0.82676M 1.53M 6.89M 7.03M 13.06M
Change to netincome 1.18M -2.32075M 3.46M 2.20M -0.49905M
Capital expenditures 1.53M 0.49M 3.57M 8.87M 6.52M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -9.42215M -0.85153M -3.11017M -0.87212M 0.79M
Stock based compensation 1.11M -3.47958M 2.63M 2.06M -
Other non cash items -3.97054M -2.66199M 3.24M 2.93M 2.88M
Free cash flow -8.14076M -2.54896M -3.81894M -9.29654M -9.88994M

Fundamentals

  • Previous Close 2.11
  • Market Cap1484.00M
  • Volume810061
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.24399M
  • Revenue TTM83.47M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM 53.80M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PNV
Polynovo Ltd
0.04 1.90% 2.15 - 140.85 17.37 21.49 17.51 647.42
COH
Cochlear Ltd
-12.31 3.79% 312.61 60.26 46.30 9.75 11.76 9.62 36.63
AVR
Anteris Technologies Ltd
-0.2 1.04% 19.00 - - 104.23 14.98 95.15 -5.9152
AVH
Avita Therapeutics Inc
0.17 6.75% 2.69 - - 8.59 5.71 6.72 -10.0538
EBR
Ebr Systems Inc CDR
-0.015 1.39% 1.06 - - - 5.68 - -7.482

Reports Covered

Stock Research & News

Profile

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Polynovo Ltd

320 Lorimer Street, Port Melbourne, VIC, Australia, 3207

Key Executives

Name Title Year Born
Mr. Jan-Marcel Gielen C.A. CFO & Company Sec. NA
Dr. David McQuillan Ph.D. Chief Technical & Scientific Officer NA
Mr. Swami Raote BPHARM, M.B.A. CEO & Director NA
Mr. Ahmed Hassan Director of Operations NA
Ms. Teena Chadha APAC Marketing & Distributor Mang. NA
Ms. Monica Benyk HR Mang. NA
Dr. Tim Moore Principal Scientist NA
Mr. Edward Graubart Sr. VP of Sales & Marketing (Americas) NA
Mr. Jan-Marcel Gielen C.A. CFO & Company Secretary NA
Mr. Philip Scorgie Chief Information Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).